Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
about
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesEfficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisLong-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.Current therapy of myelodysplastic syndromesCombination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesLenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletionSubsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesUpdate on the pharmacotherapy for myelodysplastic syndromes.Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).Guidelines for the diagnosis and management of adult myelodysplastic syndromes.
P2860
Q26778754-D704C66B-27A2-4D59-BBDD-70B8BECA09BCQ33436627-ADCD61BA-F88E-4078-9E85-D5D7821F7C7BQ33675946-A857F894-74C5-45B3-9F29-67D84ED3BA39Q34013796-E80B1A74-50D4-4913-B271-6802CA148314Q34342944-4B759B64-59FF-4440-ACAB-24E21184CFD1Q34783754-B8DD9CDA-FDD8-417D-BD9D-D2DB891E7F5EQ36446821-FA22D960-2F26-4C7F-90AE-E1DAFBBB2003Q37075929-05AE35D5-EE53-4B1F-AE8E-9645405259BCQ37094962-FF744B1F-3F5D-4048-A772-1D3182362118Q37441528-4B84366D-D0EA-48C4-9FEC-68531DE9FD7EQ38135713-5D5B68A1-E4B4-4C95-BEA2-90F41F9BA8F7Q38235662-FE960F37-60CB-4FE0-BE5C-17129A667D69Q38415206-799D0071-B409-40B7-8DAC-ADC08D1F926EQ38758162-1FE614BA-1F1E-4B3A-A036-00EF874F2BE5Q41156034-557DAB65-29C0-477A-9390-1B4ED40BDFBEQ41748682-22F9BF97-40AB-4573-9032-3E34D44E6C7AQ50463311-8806A0D1-9E94-4878-83BE-97F7741A9FF1Q52852892-24BCA7E5-D901-4516-B590-17BCDEF07038Q54392826-C856968B-3D6E-42B7-8458-824630AEACA6
P2860
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lenalidomide does not increase ...... l(5q): a comparative analysis.
@en
type
label
Lenalidomide does not increase ...... l(5q): a comparative analysis.
@en
prefLabel
Lenalidomide does not increase ...... l(5q): a comparative analysis.
@en
P2093
P2860
P356
P1433
P1476
Lenalidomide does not increase ...... el(5q): a comparative analysis
@en
P2093
A A Giagounidis
A Glasmacher
A Kuendgen
International Working Group on MDS with del(5q)
J Backstrom
N A Brandenburg
P2860
P2888
P304
P356
10.1038/LEU.2012.369
P577
2012-12-21T00:00:00Z